Humacyte, Inc. Common Stock (HUMA) is a publicly traded Healthcare sector company. As of September 15, 2026, HUMA trades at $0.54 with a market cap of $157.68M and a P/E ratio of -2.16. HUMA moved -3.19% today. Year to date, HUMA is -41.59%; over the trailing twelve months it is -61.84%. Its 52-week range spans $0.53 to $4.85. Analyst consensus is strong buy with an average price target of $2.06. Rallies surfaces HUMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for HUMA combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $0.54 |
| Market Cap | $157.68M |
| P/E Ratio | -2.16 |
| EPS | $-0.26 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.85 |
| 52-Week Low | $0.53 |
| Volume | 1.57M |
| Avg Volume | 0 |
| Revenue (TTM) | $2.04M |
| Net Income | $-40.83M |
| Gross Margin | -376.06% |
4 analysts cover HUMA: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $2.06.